サンプル依頼リスト カート
  • English
  • Korean
表紙：外陰がんの世界市場-2023年～2030年
市場調査レポート
商品コード
1316306

外陰がんの世界市場-2023年～2030年

Global Vulvar Cancer Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
外陰がんの世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の外陰がん市場は、2022年に5億4,820万米ドルに達し、2030年には8億6,180万米ドルに達することで有利な成長が予測されています。世界の外陰がん市場は予測期間（2023-2030年）にCAGR 5.9%を示すと予測されます。新薬の研究開発が進んでいることが、外陰がん市場動向の需要を押し上げています。

外陰がん市場は著しい成長を遂げています。近年、外陰がんの治療に対する標的療法や免疫療法への関心が高まっています。製薬企業や研究者は、より効果的で個別化された治療法を開発するための革新的なアプローチを模索しています。外陰がん患者の転帰を改善するための免疫チェックポイント阻害剤や分子標的薬などの標的療法の有効性を評価するための臨床試験が進行中です。

世界の外陰がん市場は、外陰がんの有病率の増加、精密医療への注目の高まり、治療革新に対する需要の増加、意識の高まり、外陰がん治療選択肢の技術的進歩などの要因によって牽引されています。

市場力学

治療イノベーションに対する需要の高まりが外陰がん市場の成長を牽引

外陰がんの治療イノベーションに対する需要は、治療成績を改善し、患者の生存率を高めたいという願望が原動力となっています。継続的な研究開発は、標的療法、免疫療法、併用療法を含む新規治療アプローチの特定を目指しています。これらの技術革新は、より効果的で個別化された治療選択肢を提供し、患者の予後改善につながる可能性を秘めています。患者や医療提供者が治療選択肢の改善を求める中、治療イノベーションに対する需要が外陰がん市場の成長を牽引しています。

外陰がんの治療革新は、標的医療や個別化医療へのアプローチを中心に展開されるようになってきています。分子プロファイリング、バイオマーカー同定、遺伝子検査の進歩により、分子レベルでの疾患理解が深まる。この知識は、個々の腫瘍の遺伝子変化や分子的特徴に特異的に対処する標的療法の開発を可能にします。個別化医療は、各患者の特性に合わせた治療計画を立て、有効性を最大化し、副作用を最小化することを目的としています。

外陰がんに対する意識の高まりも外陰がん市場の成長を促進する

外陰がんを対象とした啓発活動は、医療サービスへのアクセスを改善することにも重点を置いています。定期的な健康診断の重要性と専門的ケアの利用可能性について個人を教育することで、啓発キャンペーンは外陰がんに関連する医療サービスの需要増加を促進します。これには、婦人科医、腫瘍医、その他の専門家への相談、スクリーニングプログラム、診断検査、治療施設へのアクセスが含まれます。その結果、患者の受診や医療サービスの利用が増加し、外陰がん市場の成長を牽引しています。

啓発キャンペーンは、外陰がん、治療選択肢、支援資源に関する知識を提供することで、患者とその家族に力を与えます。力を与えられた患者は、治療方針の決定に積極的に参加し、セカンドオピニオンを求め、利用可能な治療選択肢を検討する可能性が高まります。このような患者の参加意識の高まりは、革新的な治療法に対する需要を促進し、医療提供者や製薬会社が、十分な情報を得た患者の特定のニーズや嗜好に対応するソリューションの開発に注力することを促します。

例えば、2023年7月22日、Physicians'Education Resource（PER）は、特に外陰がんと関連する婦人科がんの認識と適切な治療のために、女性の健康の未来に関する第4回年次国際会議を開催しました。

高い治療費が市場の成長を妨げる

外陰がんの治療費は高額であるため、患者にとって経済的な障壁となり、必要な治療やサービスを受けることが難しくなります。治療費には手術、放射線療法、化学療法、標的療法、支持療法などが含まれ、高額になる可能性があります。経済的負担は、一部の患者が適時適切な治療を受けることを躊躇させ、治療の遅れや不十分な治療につながります。これは患者数を減少させ、治療に対する全体的な需要を制限するため、市場の成長に影響を与える可能性があります。

COVID-19の影響分析

COVID-19の大流行は世界の外陰がん市場に大きな影響を与えました。パンデミックは、がん検診や診断処置を含む日常的な医療サービスの中断につながっています。多くの医療施設はCOVID-19患者で溢れかえり、緊急でない診療予約や処置の延期につながっています。外陰がん患者の診断と治療開始のこのような遅れは、病気の進行と予後不良をもたらしました。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は世界の外陰がん市場に中程度の影響を与えると推定されます。ロシア・ウクライナ紛争は、外陰がん分野における国際的な研究開発協力を混乱させる。政治的緊張、渡航制限、リソースの再配分などにより、異なる国の研究者、研究機関、製薬企業間の共同研究が阻害されます。この混乱は、新規治療、臨床試験、外陰がん市場の全体的な進歩の進行を遅らせる。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 治療イノベーションに対する需要の増加
      • 外陰がんに対する意識の高まり
    • 抑制要因
      • 治療に伴う副作用
    • 機会
      • 技術の進歩と新製品の上市
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 がんタイプ別

  • 外陰扁平上皮がん
  • 腺がん
  • 基底細胞がん
  • 肉腫
  • 外陰黒色腫
  • その他

第8章 治療タイプ別

  • 化学療法
  • 手術
  • 放射線療法
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • がん研究機関
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東およびアフリカ
    • 主な地域別ダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Pfizer Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • ISA Pharmaceuticals
  • Ono Pharmaceutical Co., Ltd.
  • AstraZeneca
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Sanofi
  • PDS Biotechnology Corporation
  • Novartis AG
  • Merck & Co.

第13章 付録

目次
Product Code: PH3387

Market Overview

The global vulvar cancer market reached US$ 548.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 861.8 million by 2030. The global vulvar cancer market is expected to exhibit a CAGR of 5.9% during the forecast period (2023-2030). The ongoing research and development efforts for novel drugs are driving up demand for vulvar cancer market trends.

The vulvar cancer market is experiencing significant growth. In recent years, there has been a growing interest in targeted therapies and immunotherapies for the treatment of vulvar cancer. Pharmaceutical companies and researchers are exploring innovative approaches to develop more effective and personalized treatments. Clinical trials are underway to evaluate the efficacy of targeted therapies, such as immune checkpoint inhibitors and molecularly targeted agents, in improving outcomes for patients with vulvar cancer.

The global vulvar cancer market is driven by the factors such as the increasing prevalence of vulvar cancers, rising focus on precision medicine, increasing demand for therapeutic innovations, rising awareness, and technological advancements in vulvar cancer treatment options.

Market Dynamics

Rising Demand for Therapeutic Innovations Drives the Growth of the Vulvar Cancer Market

The demand for therapeutic innovations in vulvar cancer is driven by the desire to improve treatment outcomes and enhance patient survival rates. Continuous research and development efforts aim to identify novel treatment approaches, including targeted therapies, immunotherapies, and combination therapies. These innovations have the potential to provide more effective and personalized treatment options, leading to better patient outcomes. As patients and healthcare providers seek improved treatment options, the demand for therapeutic innovations drives the growth of the vulvar cancer market.

Therapeutic innovations in vulvar cancer increasingly revolve around targeted and personalized medicine approaches. Advances in molecular profiling, biomarker identification, and genetic testing enable a deeper understanding of the disease at a molecular level. This knowledge allows for the development of targeted therapies that specifically address the genetic alterations or molecular characteristics of individual tumors. Personalized medicine aims to tailor treatment plans to the unique characteristics of each patient, maximizing efficacy and minimizing adverse effects.

Rising Awareness About Vulvar Cancers Also Drives the Growth of the Vulvar Cancer Market

Awareness initiatives aimed at vulvar cancers also focus on improving access to healthcare services. By educating individuals about the importance of regular health check-ups and the availability of specialized care, awareness campaigns drive increased demand for healthcare services related to vulvar cancers. This includes consultations with gynecologists, oncologists, and other specialists, as well as access to screening programs, diagnostic tests, and treatment facilities. The resulting increase in patient visits and utilization of healthcare services drives the growth of the vulvar cancer market.

Awareness campaigns empower patients and their families by providing them with knowledge about vulvar cancers, treatment options, and support resources. Empowered patients are more likely to actively participate in their treatment decisions, seek second opinions, and explore available treatment options. This increased patient engagement drives the demand for innovative therapies and encourages healthcare providers and pharmaceutical companies to focus on developing solutions that cater to the specific needs and preferences of informed patients.

For instance, On July 22, 2023, Physicians' Education Resource (PER) conducted the 4th Annual International Congress on the Future of Women's Health, especially for the awareness and appropriate treatments of vulvar cancer and related gynecological cancers.

The High Cost of Treatment will Hamper the Growth of the Market

The high cost of vulvar cancer treatment can create financial barriers for patients, making it difficult for them to afford the necessary therapies and services. Treatment costs include surgery, radiation therapy, chemotherapy, targeted therapies, and supportive care, which can be expensive. The financial burden deters some patients from seeking timely and appropriate treatment, leading to delayed or inadequate care. This can impact market growth as it reduces the patient pool and limits the overall demand for treatments.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global vulvar cancer market. The pandemic led to disruptions in routine healthcare services, including cancer screenings and diagnostic procedures. Many healthcare facilities were overwhelmed with COVID-19 patients, leading to the postponement of non-urgent medical appointments and procedures. This delay in diagnosis and treatment initiation for vulvar cancer patients has resulted in disease progression and poor outcomes.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global vulvar cancer market. The Russia-Ukraine conflict disrupts international research and development collaborations in the field of vulvar cancer. Collaborative efforts between researchers, institutions, and pharmaceutical companies from different countries are hampered due to political tensions, travel restrictions, or resource reallocations. This disruption slows down the progress of novel treatments, clinical trials, and the overall advancement of the vulvar cancer market.

Segment Analysis

The global vulvar cancer market is segmented based on cancer type, treatment type, end user, and region.

Vulvar Squamous Cell Carcinoma from the Cancer Type Segment Accounted for Approximately 37.8% of the Vulvar Cancer Market Share

Vulvar squamous cell carcinoma has a higher incidence compared to other types of vulvar cancer, such as adenocarcinoma or melanoma. The majority of vulvar cancer cases diagnosed are of the squamous cell carcinoma subtype. The higher incidence of vulvar squamous cell carcinoma translates into a larger patient population seeking treatment, leading to a dominant market share.

Clinical trials are a vital component of advancing cancer treatment options. The segment's dominance in the market share attracts investment in clinical trials and drug development efforts. Pharmaceutical companies and research organizations conduct trials to evaluate the safety and efficacy of new therapies or combination treatments specifically for vulvar squamous cell carcinoma. The outcomes of these trials contribute to the growth of the VSCC market segment by expanding the available treatment options for patients.

For instance, on May 17, 2023, Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced that its first patient with squamous cell carcinoma of the vulva has been treated in a feasibility and safety study of Alpha DaRT at Addenbrookes Hospital of the Cambridge University Hospitals NHS Foundation Trust in Cambridge, England.

Geographical Analysis

North America Accounted for Approximately 40.3% of the Market Share Owing to the Advanced Healthcare Infrastructure and Technological Advancements

North America, particularly the United States and Canada, has a highly developed healthcare infrastructure characterized by a network of well-equipped hospitals, specialized cancer centers, and advanced medical facilities. This infrastructure enables efficient diagnosis, treatment, and management of vulvar cancer. The availability of comprehensive healthcare services, including advanced imaging technologies, surgical techniques, and supportive care, contributes to better patient outcomes and drives market growth in the region.

North America is known for its continuous advancements in medical technologies and innovation. The region is at the forefront of research and development in the field of oncology, including vulvar cancer. Technological advancements such as advanced diagnostic tools, molecular profiling, targeted therapies, and precision medicine have significantly impacted the management of vulvar cancer.

Competitive Landscape

The major global players in the vulvar cancer market include: Pfizer Inc., ISA Pharmaceuticals, Ono Pharmaceutical Co., Ltd., AstraZeneca, Celgene Corporation, Bristol-Myers Squibb Company, Sanofi, PDS Biotechnology Corporation, Novartis AG, and Merck & Co.

Why Purchase the Report?

  • To visualize the global vulvar cancer market segmentation based on cancer type, treatment type, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of vulvar cancer market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global vulvar cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Cancer Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Therapeutic Innovations
      • 4.1.1.2. Rising Awareness About Vulvar Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements and Novel Product Launches
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Vulvar Squamous Cell Carcinoma *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adenocarcinoma
  • 7.4. Basal Cell Carcinoma
  • 7.5. Sarcoma
  • 7.6. Vulvar Melanoma
  • 7.7. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Chemotherapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Surgery
  • 8.4. Radiation Therapy
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Cancer Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. ISA Pharmaceuticals
  • 12.3. Ono Pharmaceutical Co., Ltd.
  • 12.4. AstraZeneca
  • 12.5. Celgene Corporation
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. Sanofi
  • 12.8. PDS Biotechnology Corporation
  • 12.9. Novartis AG
  • 12.10. Merck & Co.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us